The accredited product is a generic model of Sunovion Pharmaceuticals Inc’s Brovana.
The firm has obtained closing approval for its abbreviated new drug software (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla stated in a regulatory submitting.
Brovana is utilized in upkeep remedy of bronchoconstriction in sufferers with persistent obstructive pulmonary illness (COPD), together with persistent bronchitis and emphysema.
Quoting IQVIA (IMS Health) knowledge, Cipla stated Brovana had US gross sales of roughly USD 438 million for the 12-month interval ending April 2021.
The product is obtainable for delivery instantly, it added.